Addendum
Pembrolizumab (renal cell carcinoma) – Addendum to Commission A22-71
Report documents
-
Addendum
Pembrolizumab (renal cell carcinoma) – Addendum to Commission A22-71
Dossier assessment
Indication:
Adjuvant treatment of adult patients with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
Result of dossier assessment:
After addendum now hint of non-quantifiable added benefit
Additional information
Federal Joint Committee (G-BA)
2023-01-19 A G-BA decision was published.
Project details
- Project no.
- A22-128
- Commission
- Commission awarded on 06.12.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V
Status: Commission completed